STENOCARE: Status from Founders’ transactions to satisfy demand for subscription rights
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
The Founders of STENOCARE today agreed to sell subscription rights in the ongoing rights issue, in order to satisfy market demand.
A total of 210.000 rights were sold with total proceed of DKK 423.099
The Founders will re-invest all proceeds from the sales in the issue in order to maintain their position as “not-selling-shareholders” to the extent that the issue is not otherwise fully subscribed.
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by STENOCARE A/S for publication on June 9, 2020.
Any questions on this matter can be directed to:
Thomas Skovlund Schnegelsberg, CEO STENOCARE A/S
Telefon: +45 31770060
STENOCARE’s Certified Adviser is Keswick Global AG, Reg. FN 332389 h, Hoffingergasse 16/1/6, 1120 Vienna, Austria, telephone number +43 1 740 408045 E-mail: firstname.lastname@example.org
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil that complies with the strict Danish regulatory requirements. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.